Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
March 01 2021 - 3:45PM
Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering
engineered hematopoietic stem cell (eHSC) therapies combined with
targeted therapies for the treatment of cancer, today announced
that the Company will be participating in the Cowen 41st Annual
Health Care Conference, which will take place virtually on March
1-4, 2021. Robert Ang, MBBS, MBA, Vor’s President and Chief
Executive Officer, and Nathan Jorgensen, PhD, Chief Financial
Officer, are scheduled to present on Thursday, March 4, 2021, at
1:30 p.m. E.T.
About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform
the lives of cancer patients by pioneering engineered hematopoietic
stem cell (eHSC) therapies to create next-generation,
treatment-resistant transplants that unlock the potential of
targeted therapies. By removing biologically redundant proteins
from eHSCs, we design these cells and their progeny to be
treatment-resistant to complementary targeted therapies, thereby
enabling these therapies to selectively destroy cancerous cells
while sparing healthy cells.
Contacts:
Investor: Constantine Davides, CFAWestwicke +1 339-970-2846
constantine.davides@westwicke.com
Media: Mary Carmichael Ten Bridge Communications +1 617-413-3543
mary@tenbridgecommunications.com
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Oct 2023 to Oct 2024